| Id: | acc2441 |
| Group: | 2sens |
| Protein: | JNK2 |
| Gene Symbol: | MAPK9 |
| Protein Id: | P45984 |
| Protein Name: | MK09_HUMAN |
| PTM: | phosphorylation |
| Site: | Tyr185 |
| Site Sequence: | ACTNFMMTPYVVTRYYRAPEV |
| Disease Category: | Cancer |
| Disease: | Hepatocellular Carcinoma |
| Disease Subtype: | |
| Disease Cellline: | HepG2 |
| Disease Info: | |
| Drug: | TRAIL + 5-fluorouracil (10-FU) |
| Drug Info: | "TRAIL (TNF-related apoptosis-inducing ligand) is a member of the tumor necrosis factor (TNF) family that selectively induces apoptosis in tumor cells by binding to death receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2), while sparing normal cells, and enhances the efficacy of chemotherapy and radiotherapy. 5-Fluorouracil (5-FU) is a pyrimidine analog antimetabolite chemotherapeutic agent that inhibits thymidylate synthase, thereby interfering with DNA synthesis, and is widely used in the treatment of colorectal, gastric, breast, and other solid tumors." |
| Effect: | inhibit |
| Effect Info: | "GSH depletion enhances TRAIL/5-FU-induced tumor cell death through JNK2 phosphorylation, while its effect on TRAIL/CDDP is mainly to reduce the detoxification mechanism." |
| Note: | drug comb |
| Score: | 5.0 |
| Pubmed(PMID): | 15837763 |
| Sentence Index: | 15837763_9-10 |
| Sentence: | "RESULTS: GSH depletion enhanced apoptosis induced by TRAIL/cisplatin (CDDP) or TRAIL/5-fluorouracil (5-FU) combinations in both human HT29 colon carcinoma and HepG2 hepatocarcinoma cells, whereas it enhanced cytotoxicity induced only by TRAIL/CDDP in human primary hepatocytes. Our results further suggested that GSH depletion enhanced SAPK/JNK phosphorylation upon TRAIL/5-FU exposure and likely reduced the detoxification mechanisms of CDDP in HT29 cells." |
Sequence & Structure:
MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRPFQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIHMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQLGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSKMLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEVMDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR
Select PDB:
| Target | Drug name | MOA | Phase | Status | Disease | Source |
|---|---|---|---|---|---|---|
| MAPK9 | BENTAMAPIMOD | c-Jun N-terminal kinase, JNK inhibitor | 2 | Completed | endometriosis | ClinicalTrials |
| MAPK9 | TANZISERTIB | c-Jun N-terminal kinase 2 inhibitor | 2 | Terminated | idiopathic pulmonary fibrosis | ClinicalTrials |
| MAPK9 | TANZISERTIB | c-Jun N-terminal kinase 2 inhibitor | 2 | Terminated | lupus erythematosus | ClinicalTrials |
| MAPK9 | CC-401 | c-Jun N-terminal kinase 2 inhibitor | 1 | Terminated | myeloid leukemia | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTAC| MAPK9-Tyr185 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | |
| ccRCC | |
| GBM | 0.707 |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | -0.707 |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
